Northwire Canada EditionMonday, August 24, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% EML 0.225 −4.3% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% EML 0.225 −4.3%
Financings Routine −

Lophos Holdings Inc. Announces Partial Revocation of Cease Trade Order, Proposed Consolidation and Financing

Regulatory Survival Financing Keeps Halted Psychedelic Micro-Cap Afloat Amid CSDL Loss

By The Northwire Desk — AI Analysis Jul 01, 2026 · 10:20 MESC · 0.01 Lophos Holdings Inc.
Executive Summary
  • Lophos Holdings Inc. received a Partial Revocation Order from the BCSC, permitting a $530,000 private placement despite an existing failure-to-file cease trade order (FFCTO).
  • The financing consists of up to 17,666,666 units priced at $0.03 per unit, each containing one common share and one warrant exercisable at $0.05 for 36 months.
  • A 1-for-3 share consolidation will precede the financing, reducing the outstanding share count to approximately 29,328,224 post-consolidation shares.
  • Proceeds are strictly allocated to updating continuous disclosure records, paying regulatory fees and penalties, covering financing costs, and funding basic operating expenses.
  • The company previously lost its site-specific Controlled Substances Dealer's Licence (CSDL) in June after disposing of its Napanee, Ontario facility, effectively halting direct regulated operations.
Material Impact
  • The financing is a compliance-driven survival measure rather than a growth catalyst. Raising $530,000 to clear regulatory backlogs and maintain corporate existence highlights severe liquidity constraints.
  • The 1-for-3 consolidation and warrant issuance are standard micro-cap tactics but introduce immediate dilution for existing shareholders.
  • Loss of the CSDL and the ongoing FFCTO mean the company cannot trade its stock or operate its core licensed activities until further regulatory and operational hurdles are cleared.
  • The news does not alter the fundamental risk profile; it merely extends the company's runway to address administrative and regulatory deficiencies.
MESC · Price
Company Overview
  • Lophos Holdings Inc. is a Canadian entity focused on the research and development of controlled substances, including MDMA, ketamine, LSD, DMT, mescaline, psilocin, and psilocybin.
  • The company previously operated a 10,000-square-foot facility in Napanee, Ontario, under a site-specific CSDL.
  • Following the disposition of the facility via mortgage enforcement proceedings, the CSDL was lost. Management is now pivoting to a partnership-based model, leveraging third-party license holders and contract research organizations to continue its pipeline without heavy infrastructure expenditures.
  • The company is currently under a failure-to-file cease trade order, halting all public trading.
Read the original news release →

More from Lophos Holdings Inc.

Jun 11, 2026 · 21:08

Dormant Psychedelic Developer Grapples with License Loss and Ongoing Trading Halt

Regulatory